GPCR Logo

Structure Therapeutics Inc. (GPCR) 

NASDAQ
Market Cap
$1.74B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
546 of 774
Rank in Industry
293 of 432

Largest Insider Buys in Sector

GPCR Stock Price History Chart

GPCR Stock Performance

About Structure Therapeutics Inc.

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular …

Insider Activity of Structure Therapeutics Inc.

Over the last 12 months, insiders at Structure Therapeutics Inc. have bought $0 and sold $0 worth of Structure Therapeutics Inc. stock.

On average, over the past 5 years, insiders at Structure Therapeutics Inc. have bought $0 and sold $0 worth of stock each year.

There was no buying activity among insiders over the last 12 months.

List of Insider Buy and Sell Transactions, Structure Therapeutics Inc.

2024-06-10SaleCHIEF EXECUTIVE OFFICER
185,000
$0$0-26.31%
2024-06-03SaleCHIEF SCIENTIFIC OFFICER
35,400
$0$0-25.58%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.